Sunday, January 29, 2023

Ezetimibe combined with moderate-intensity statin would benefit patients with diabetes

A recent study found that this therapy option works in patients who do not tolerate high-intensity statins.

Luisa Ochoa

January 17, 2023 | , Reading Time: 4 min

Statins are used to prevent cardiovascular diseases and to treat abnormal levels of lipids in the blood. Photo: shutterstock.

One study evaluated the effect of combination therapy with a moderate-intensity statin and the drug ezetimibe versus high-intensity statin monotherapy in patients suffering from low diabetes Mellitus and disease Heart Atherosclerotic.

According to medical information, ezetimibe is used to lower the amount of cholesterol and other fats present in the blood of patients.

The study was conducted using pre-specified and stratified subgroup analysis of 1,398 patients. diabetes In racing test. The researchers who led the project had three-year total mortality as their primary endpoint. HeartSerious cardiac complications or non-fatal stroke.

37% of the total number of patients had diabetes Mellitus at baseline. On the other hand, the incidence of the primary outcome was 10% and 11.3% in patients diabetes Randomized to high-intensity statin monotherapy versus ezetimibe combination therapy.

Combination treatment equivalent to high-intensity statin monotherapy

The study authors reported dose interruption or reduction of study drug related to intolerance in 5.2% and 8.7% of patients in each arm, respectively.

Similarly, the proportion with LDL cholesterol <70 mg/dL was consistently higher with ezetimibe combination therapy at 1 year (81.0% vs. 64.1%), 2 years (83.1% vs. 70.2%) and 3 years (79.9% vs. 66.8%) for all.

Therefore, in patients diabetes and disease Heart In atherosclerotic patients, ezetimibe combined with moderate-intensity statin therapy was comparable to high-intensity statin monotherapy in related cardiovascular events.

For the investigators, the combination was associated with fewer treatment interruptions or dose reductions due to intolerance and a greater number of patients achieving low-density lipoprotein cholesterol levels <70 mg/dL.

Alternative for patients who do not tolerate high-intensity statins

“The findings support the use of moderate-intensity statin combination therapy with ezetimibe as a suitable alternative to high-intensity monotherapy if high-intensity statins are not tolerated or further reduction of LDL cholesterol levels is needed.” occur, as current guidelines suggest,” they noted.

american standards diabetes Association of 2022, indicates that statins are also the drug of choice for lowering LDL cholesterol levels and preventing damage Heart of diabetic patients. High-intensity statins are the drug of choice in secondary prevention

Among the study’s recommendations is that patients with diabetes and disease Heart Concomitant atherosclerosis increases early risk of disease events HeartThe authors therefore recommend that they receive a high-intensity statin to lower LDL cholesterol levels.

Despite this, many patients are unable to tolerate high-dose statins because of their side effects.

One of the study’s limitations is that the researchers analyzed a relatively small sample of patients. diabetesWith many minor incidents and relatively little follow-up.

Access the study here.

Nation World News Desk
Nation World News Desk
Nation World News is the fastest emerging news website covering all the latest news, world’s top stories, science news entertainment sports cricket’s latest discoveries, new technology gadgets, politics news, and more.
Latest news
Related news


Please enter your comment!
Please enter your name here